This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO) (AbCLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06242925
Recruitment Status : Recruiting
First Posted : February 5, 2024
Last Update Posted : February 22, 2024
Sponsor:
Collaborators:
InentoRR MD
LAC+USC Medical Center
Information provided by (Responsible Party):
Tufts Medical Center

Brief Summary:

The goal of this multicenter, prospective Cohort Interventional study is to perform a pilot study of the AbCLO (Abdominal Wall Closure) device in patients with Open Abdomen. The main question it aims to answer is:

• Does the Abdominal Wall Closure Device (AbCLO) increase the likelihood of primary facial closure in cases of open abdomen when compared to historical controls?

Participants will be cases of open abdomen who underwent emergency surgery for Trauma or Acute Care Surgery, will have the AbCLO device. These will be compared to historical controls managed at the same center.


Condition or disease Intervention/treatment Phase
Open Abdomen Device: AbCLO (Abdominal Wall Closure) Device Not Applicable

Detailed Description:

This is a multi-center matched prospective cohort study. It will be performed in collaboration between 2 centers in the USA: Tufts Medical Center (TMC) and Los Angeles County + University of Southern California (LAC + USC) Medical Center.

The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).

The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

The total sample size is 80 patients, 20 in the treatment arm (15 from TMC and 5 from LAC+USC) and 60 in the control arm (45 from TMC and 15 from LAC+USC). The treatment arm will be matched to historical control based on the following pre-specified variables:

  1. Age
  2. Diagnosis: trauma case vs acute general surgery cases,
  3. Assessment of severity: Injury severity scores (ISS) for Trauma cases and APACHEII score for acute general surgery cases

Outcome Data:

  1. Primary Outcome: Proportion of patients achieved primary facial closure within 14 days. (This is defined as approximation of the fascia on either side of the midline to perform suture closure without using any mesh or additional procedures. From our experience, most open abdomen is usually closed within 7-10 days. We decided to put any closure more than 14 days is considered failure of the device).
  2. Proportion of patients that require component separation and/or mesh closure to obtain fascial closure, (if we need to use mesh or do additional procedure to close the abdomen, this is considered failure rate of the ABCLO device)
  3. Percentage of patients requiring additional device, such as Whitman's patch to maintain fascial closure. (this is also considered failure of the ABCLO device)
  4. The time from inclusion to complete abdominal wall fascial closure (as defined above) prior to discharge. (Duration of patients that require the abdomen to be open)
  5. Percentage of patients developing pressure ulcers (as a possible complication of the device)
  6. Duration of mechanical ventilation, ICU length of stay and hospital length of stay (to examine the indirect effects of primary fascial closure on these outcomes)
  7. Total cost per patient before and after application of the ABCLO from ICU admission to closure of the abdomen.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: This is a multi-center, matched, interventional prospective cohort study compared to historical cohort.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO)- Pilot Study
Estimated Study Start Date : February 2024
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ABCLO Group
The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).
Device: AbCLO (Abdominal Wall Closure) Device
They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.

No Intervention: Historical Controls

The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

At TMC, we have a previously collected data bank of all open abdomen managed at our center. This data bank is approved by IRB. This data bank has 170 patients in total. we will use 45 patients from the data bank to be matched to the interventional group (15 patients) to have a total of 60 patients from TMC.

As of LAC+USC Medical Center, they will provide historical controls from the trauma registry.




Primary Outcome Measures :
  1. Primary facial closure [ Time Frame: 14 days ]
    Proportion of patients achieved primary facial closure within 14 days. (This is defined as approximation of the fascia on either side of the midline to perform suture closure without using any mesh or additional procedures. From our experience, most open abdomen is usually closed within 7-10 days. We decided to put any closure more than 14 days is considered failure of the device).


Secondary Outcome Measures :
  1. Additional procedures/Mesh [ Time Frame: 14 days ]
    Proportion of patients that require component separation and/or mesh closure to obtain fascial closure, (if we need to use mesh or do additional procedure to close the abdomen, this is considered failure rate of the ABCLO device)

  2. The need for additional device [ Time Frame: 14 days ]
    Percentage of patients requiring additional device, such as Whitman's patch to maintain fascial closure. (this is also considered failure of the ABCLO device)

  3. Timeframe required to obtain primary facial closure [ Time Frame: 14 days ]
    The time from inclusion to complete abdominal wall fascial closure (as defined above) prior to discharge. (Duration of patients that require the abdomen to be open)

  4. Side effects related to the device [ Time Frame: 14 days ]
    Percentage of patients developing pressure ulcers (as a possible complication of the device)

  5. Intensive care Data [ Time Frame: 14 days ]
    Duration of mechanical ventilation, ICU length of stay and hospital length of stay (to examine the indirect effects of primary fascial closure on these outcomes)

  6. Cost comparison [ Time Frame: 14 days ]
    Total cost per patient before and after application of the ABCLO from ICU admission to closure of the abdomen.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults more than 18 years of age, and less than 100 years of age
  2. Admitted to the trauma and acute care surgery service, underwent damage control laparotomy and left with an open abdomen (OA). Trauma or Emergency General Surgery, such as perforated viscus, Bowel obstruction or abdominal compartment syndrome.

Exclusion Criteria:

  1. Pregnant patients
  2. Patients who lost any portion of the abdominal wall that preclude primary abdominal wall closure
  3. Patient who previously had a ventral hernia before having an open abdomen
  4. Patient who already had a previous mesh repair
  5. Burn patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06242925


Contacts
Layout table for location contacts
Contact: Mohammed A. Bawazeer, MD, FACS, FRCSC 617-636-4488 mohammed.bawazeer@tuftsmedicine.org
Contact: Ritika Dinesh 617-636-5717 ritika.dinesh@tuftsmedicalcenter.org

Locations
Layout table for location information
United States, California
Los Angeles County + University of Sothern California Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Morgan Schellenberg, MD MPH FRCSC FACS         
Sub-Investigator: Kenji Inaba, MD         
United States, Massachusetts
Tufts Medical center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Ritika Dinesh       ritika.dinesh@tuftsmedicalcenter.org   
Contact: Stephanie Gomez       Stephanie.Gomez@tuftsmedicine.org   
Sub-Investigator: Nikolay Bugaev, MD         
Sub-Investigator: Horacio Hojman, MD         
Sub-Investigator: Woon Cho Kim, MD         
Sub-Investigator: Madeline Velez, MD         
Principal Investigator: Mohammed Bawazeer, MD         
Sponsors and Collaborators
Tufts Medical Center
InentoRR MD
LAC+USC Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Mohammed A. Bawazeer, MD Tufts Medical Center
Publications:
Rezende-Neto JB, et al. Vaccum Pack technique for temporary abdominal wound closure. Rev Col Bras Cir 2007; 34:336-339.
Rezende-Neto J, Al Kefeiri G, Semprun C, Rizoli S, Rotstein O. A non-invasive device for primary facial closure of the "open Abdomen" to prevent the "homeless bowel": a prospective, randomized, clinical tria abstract]. In: Proceedings of the Trauma Association of Canada 2017 Scientific Meeting & Conference; 2017 Feb 23-24, 2017; Vancouver (AB). Abstract 80.

Layout table for additonal information
Responsible Party: Tufts Medical Center
ClinicalTrials.gov Identifier: NCT06242925    
Other Study ID Numbers: STUDY00003444
First Posted: February 5, 2024    Key Record Dates
Last Update Posted: February 22, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Tufts Medical Center:
Open Abdomen
Trauma
Acute Care Surgery
Emergency General Surgery